Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 4, 2007, Pages 419-427

  Yanaihara, Tomoko ^a   Yokoba, Masanori ^a   Onoda, Sayaka ^a   Yamamoto, Michiko ^a   Ryuge, Shinichiro ^a   Hagiri, Shintaro ^a   Katagiri, Masato ^a   Wada, Mayuko ^a   Mitsufuji, Hisashi ^a   Kubota, Masaru ^a   Arai, Susumu ^a   Kobayashi, Hirosuke ^a   Yanase, Nobuo ^a   Abe, Tadashi ^a   Masuda, Noriyuki ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amrubicin; Biliary index; CPT 11; Pharmacokinetics; Topoisomerase inhibitors

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; AMRUBICIN; AMRUBICINOL; ANTIDIARRHEAL AGENT; DRUG METABOLITE; IRINOTECAN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; FATIGUE; FEMALE; HUMAN; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; KIDNEY FUNCTION; LARGE CELL CARCINOMA; LEUKOPENIA; LIVER FUNCTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 33846308140     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0279-5     Document Type: Article

References (31)

1. Bertrand R, O'Connor PM, Kerrigan D, Pommier Y (1992) Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A:743-748
2. Bugat R (2003) Irinotecan in the treatment of gastric cancer. Ann Oncol 14(Suppl 2):ii37-40
3. D'Arpa P, Beardmore C, Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919-6924
4. Friedman HS, Keir ST, Houghton PJ (2003) The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer 97:2359-2362
5. Furuse K, Ikegami H, Ariyoshi Y (1988) Two phase II studies of amrubicin (SM-5887), a novel 9-amino-anthracycline, in patients with advanced non-small cell lung cancer (NSCLC): West Japan Lung Cancer Group Trials.. Ann Oncol 9(Suppl 4):88(abstract 422)
6. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725
7. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89:1229-1238
8. Holford NH, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16:143-166
9. Ishizumi K, Ohashi N, Tanno N et al (1987) Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem 52:4477-4485
10. Kaufmann SH (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136
11. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K (1992) Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760-766
12. Korn EL, Simon R (1993) Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. J Clin Oncol 11:794-801
13. Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T et al (1995) Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 86:406-413
14. Langer CJ (2003) The global role of irinotecan in the treatment of lung cancer: 2003 update. Oncology (Huntingt) 17:30-40
15. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, Nakagawa K, Tamanoi M, Nitta T, Hirashima T et al (1993) Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782
16. Masuda N, Kudoh S, Fukuoka M (1996) Irinotecan (CPT-11): pharmacology and clinical applications. Crit Rev Oncol Hematol 24:3-26
17. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M (1989) Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 80:69-76
18. Mountain C (1997) Revisions in the international system for lung cancer. Chest 111:1710-1717
19. Negoro S, Fukuoka M, Nakamura S et al (1995) Phase I-II study of amrubicin (SM-5887), a novel 9-amino-anthracycline, by iv administration for 3 consecutive days in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 14:361
20. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16:121-128
21. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 89:1061-1066
22. Oshita F, Noda K, Nishiwaki Y, Fujita A, Kurita Y, Nakabayashi T, Tobise K, Abe S, Suzuki S, Hayashi I, Kawakami Y, Matsuda T, Tsuchiya S, Takahashi S, Tamura T, Saijo N (1997) Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 15:304-309
23. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353
24. Socinski M (2004) Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy. Clin Lung Cancer 5:274-289
25. Sumiyoshi H, Fujiwara Y, Ohune T, Yamaoka N, Tamura K, Yamakido M (1995) High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J Chromatogr B Biomed Appl 670:309-316
26. Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15:219-225
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
28. Vasey PA, Kaye SB (1997) Combined inhibition of topoisomerases I and II-is this a worthwhile/feasible strategy? Br J Cancer 76:1395-1397
29. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885
30. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067-1073
31. Yana T, Negoro S, Takada Y, Yokota S, Fukuoka M, tWJLCG (1998) Phase II study of amrubicin (SM-5887). A 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): a West Japan Lung Cancer Group trial. Proc Am Soc Clin Oncol 17:450a